

CONFIDENTIAL INFORMATION

Health Guide

Considerations to help your patients
improve their health

06/10/2025

Prepared for LINDSEY BARTON,

A recent review of pharmacy and / or medical claims has identified the following drug therapy opportunity for your patient

Bottom line: Non-adherent to diabetes medication

Action requested: Evaluate drug refill patterns

The Adherence diabetes program identifies patients whose proportion of days covered (PDC) is less than 80%. This patient's PDC is 79% over the previous 365 days. Common reasons for non-adherence may include: side effects, affordability, or changes in the drug regimen. Please provide a new prescription if the regimen has changed, and/or discuss the importance of adherence and ways to address barriers with your patient.

The most recent diabetes medication claim for which you have been identified as the prescriber is listed below.

Date Filled	Drug Name/Strength	Dispensed Quantity	Days Supply	Pharmacy Name	Pharmacy Phone	Prescriber of Record Name	Prescriber Phone
20250505	METFORMIN TAB 1000MG	180	90	WALGREENS #7746	(334) 409-0611	LINDSEY BARTON	(334) 568-2120

If you have received a profile for a patient for whom you are not the prescriber and/or have not provided care, or if this prescriber is not located here, please visit www.primetherapeutics.com/ProviderFollowUp to answer a few short questions about the incorrect patient/prescriber information. Please destroy this message to protect patient confidentiality.

IMPORTANT WARNING: We identify prescribers based on the National Provider Identifier (NPI) submitted by pharmacies on the prescription drug claims. Due to the potential for claim submission errors, please validate the above information. This information is not intended to replace your clinical judgement and is being provided to you for purposes of quality, care coordination, and other health care operations as permitted by the Health Insurance Portability and Accountability Act (HIPAA). Only a physician in direct consultation with the patient may determine whether to pursue drug therapy opportunities.

6/11/25
L. Barton
CRP